US 11,945,847 B2
Optogenetic induction of neurodegenerative disease pathologies
Christopher James Donnelly, Pittsburgh, PA (US); and Jacob R. Mann, Pittsburgh, PA (US)
Assigned to UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US)
Appl. No. 16/491,758
Filed by UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US)
PCT Filed Mar. 7, 2018, PCT No. PCT/US2018/021335
§ 371(c)(1), (2) Date Sep. 6, 2019,
PCT Pub. No. WO2018/165293, PCT Pub. Date Sep. 13, 2018.
Claims priority of provisional application 62/468,065, filed on Mar. 7, 2017.
Prior Publication US 2021/0139547 A1, May 13, 2021
Int. Cl. C07K 14/47 (2006.01); C12N 15/62 (2006.01); C12N 15/79 (2006.01); C12Q 1/00 (2006.01); G01N 33/50 (2006.01)
CPC C07K 14/47 (2013.01) [C12N 15/62 (2013.01); C12N 15/79 (2013.01); G01N 33/5008 (2013.01); G01N 2800/28 (2013.01)] 14 Claims
 
1. A nucleotide sequence encoding a chimeric polypeptide, comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein; wherein the light-induced oligomerization domain is CRY2OLIG, or a fragment thereof and wherein the low complexity domain from a neurodegenerative disease target protein is TDP-43.